SYNTAXES, biomarkers and survival in complex coronary artery disease: the intervention of secondary prevention.
作者信息
Gulati Martha, Burgess Sonya
机构信息
Division of Cardiology, University of Arizona, Phoenix, AZ, USA.
University of Sydney, Nepean Hospital, Sydney, Australia.
出版信息
EuroIntervention. 2022 Apr 22;17(18):1460-1462. doi: 10.4244/EIJ-E-22-00008.
Abstract
摘要
相似文献
1
SYNTAXES, biomarkers and survival in complex coronary artery disease: the intervention of secondary prevention.复杂冠状动脉疾病中的SYNTAX评分、生物标志物与生存情况：二级预防的干预措施
EuroIntervention. 2022 Apr 22;17(18):1460-1462. doi: 10.4244/EIJ-E-22-00008.
2
Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial.
Int J Cardiol. 2023 Jan 15;371:132-134. doi: 10.1016/j.ijcard.2022.09.003. Epub 2022 Sep 9.
3
Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.SYNTAX 评分 II 的再开发和验证：用于指导复杂冠状动脉疾病患者经皮与手术血运重建策略的个体化选择：多中心随机对照 SYNTAXES 试验的二次分析及外部队列验证。
Lancet. 2020 Oct 31;396(10260):1399-1412. doi: 10.1016/S0140-6736(20)32114-0. Epub 2020 Oct 8.
4
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗三血管病变或左主干病变患者：多中心随机对照 SYNTAX 试验 10 年随访结果。
Lancet. 2019 Oct 12;394(10206):1325-1334. doi: 10.1016/S0140-6736(19)31997-X. Epub 2019 Sep 2.
5
Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting: A Surgical Perspective.
JAMA Cardiol. 2019 Jun 1;4(6):505-506. doi: 10.1001/jamacardio.2019.1046.
6
Impact of the CABG SYNTAX score on all-cause death at 10 years: a SYNTAX Extended Survival (SYNTAXES) substudy.冠状动脉旁路移植术（CABG）SYNTAX评分对10年全因死亡的影响：一项SYNTAX延长生存（SYNTAXES）子研究。
EuroIntervention. 2021 May 17;17(1):75-77. doi: 10.4244/EIJ-D-20-00170.
7
Comparison of peri and post-procedural complications in patients undergoing revascularisation of coronary artery multivessel disease by coronary artery bypass grafting or protected percutaneous coronary intervention with the Impella 2.5 device.比较经皮冠状动脉介入治疗与冠状动脉旁路移植术联合 Impella 2.5 装置治疗冠状动脉多支血管病变患者围手术期和术后并发症。
Eur Heart J Acute Cardiovasc Care. 2019 Jun;8(4):360-368. doi: 10.1177/2048872617717687. Epub 2017 Jun 29.
8
Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease.冠心病住院患者二级预防措施的时间趋势。
Am J Med. 2015 Apr;128(4):426.e1-9. doi: 10.1016/j.amjmed.2014.11.013. Epub 2014 Nov 26.
9
Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial.SYNTAXES 试验中术前生物标志物对 10 年死亡率的影响。
EuroIntervention. 2022 Apr 22;17(18):1477-1487. doi: 10.4244/EIJ-D-21-00415.
10
Secondary Pharmacological Prevention of Coronary Artery Disease among Patients Submitted to Clinical Management, Percutaneous Coronary Intervention, or Coronary Artery Bypass Graft Surgery.临床管理、经皮冠状动脉介入治疗或冠状动脉旁路移植手术后患者的冠状动脉疾病二级药理学预防。
Arq Bras Cardiol. 2023 Feb;120(2):e20220403. doi: 10.36660/abc.20220403.
引用本文的文献
1
Narrowing disparities in PCI outcomes in women; From risk assessment, to referral pathways and outcomes.女性经皮冠状动脉介入治疗（PCI）结果方面差距的缩小；从风险评估到转诊途径及结果。
Am Heart J Plus. 2022 Nov 5;24:100225. doi: 10.1016/j.ahjo.2022.100225. eCollection 2022 Dec.
本文引用的文献
1
Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.在患有 2 型糖尿病和动脉粥样硬化性心血管疾病的患者中使用降脂、降压和降糖药物治疗。
JAMA Netw Open. 2022 Feb 1;5(2):e2148030. doi: 10.1001/jamanetworkopen.2021.48030.
2
Medication Adherence After Acute Coronary Syndrome in Women Compared With Men: A Systematic Review and Meta-Analysis.急性冠状动脉综合征后女性与男性的药物依从性：一项系统评价和荟萃分析。
Front Glob Womens Health. 2021 Feb 22;2:637398. doi: 10.3389/fgwh.2021.637398. eCollection 2021.
3
Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial.SYNTAXES 试验中术前生物标志物对 10 年死亡率的影响。
EuroIntervention. 2022 Apr 22;17(18):1477-1487. doi: 10.4244/EIJ-D-21-00415.
4
External Validation of the SYNTAX Score II 2020.SYNTAX Score II 2020 外部验证
J Am Coll Cardiol. 2021 Sep 21;78(12):1227-1238. doi: 10.1016/j.jacc.2021.07.027.
5
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.2021年欧洲心脏病学会临床实践中心血管疾病预防指南。
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
6
Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.慢性肾脏病中的心血管疾病：病理生理学见解与治疗选择。
Circulation. 2021 Mar 16;143(11):1157-1172. doi: 10.1161/CIRCULATIONAHA.120.050686. Epub 2021 Mar 15.
7
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
8
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
9
Colchicine in Patients with Chronic Coronary Disease.秋水仙碱治疗慢性冠心病
N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31.
10
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.心梗后小剂量秋水仙碱的疗效和安全性。
N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
Zotero 插件